Korro Bio, Inc. (KRRO)
(Delayed Data from NSDQ)
$36.36 USD
+0.39 (1.08%)
Updated Aug 13, 2024 04:00 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
Korro Bio, Inc. [KRRO]
Reports for Purchase
Showing records 1 - 8 ( 8 total )
Company: Korro Bio, Inc.
Industry: Medical - Biomedical and Genetics
Updated KRRO-110 Preclinical Data Show Multiple Positive Trends; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Korro Bio, Inc.
Industry: Medical - Biomedical and Genetics
Major Catalysts On Track; 1Q24 Financial Results; Lowering PT to $100
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Korro Bio, Inc.
Industry: Medical - Biomedical and Genetics
Gene Juice: RNA Editing Rises to the Forefront of RNA Therapeutics
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Korro Bio, Inc.
Industry: Medical - Biomedical and Genetics
KRRO-110 Edge Vs. DNA Base Editor; 2023 Financials; Raising PT to $115
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Korro Bio, Inc.
Industry: Medical - Biomedical and Genetics
Inhibrx Acquisition Underscores Korro''s Upside Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Korro Bio, Inc.
Industry: Medical - Biomedical and Genetics
New KRRO-110 Preclinical Results Appear Favorable; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Korro Bio, Inc.
Industry: Medical - Biomedical and Genetics
KRRO-110 Selected As Lead AATD Asset; Regulatory Filing 2H24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Korro Bio, Inc.
Industry: Medical - Biomedical and Genetics
Shoot the Messenger; Precisely Editing RNA; Initiating at Buy and $100 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
|